Back to Trials
NCT06803589EARLY_PHASE1Recruiting

Growth Hormone for the Treatment of Gastroparesis

Mayo Clinic

Start Date

10/22/2024

Completion Date

12/1/2027

Summary

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Symptoms \> 6 months that have not responded satisfactorily to standard treatment. * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21 Exclusion Criteria: * Known history of GH deficiency, hypothalamic or pituitary disease * Diabetes * Prior use of GH therapy * Age-adjusted low serum IGF1 * Women on oral estrogen therapy6 * Pregnancy or nursing * History of malignant solid tumors * Obesity (BMI \> 30)History of coronary and thromboembolic diseases. * History of sarcoidosis * History of pituitary surgery * History of thyroid nodules. * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. * Failure to give informed consent.

Interventions

DRUG

Growth Hormone

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Gastroparesis

Locations

Mayo Clinic

Phoenix, Arizona 85054

United States

Mayo Clinic in Arizona

Scottsdale, Arizona 85259

United States